Dear Investor,

Last month I told investors that a Trump-backed crypto bank could be approved any day.

On August 14, it was.

Federal regulators granted conditional approval to World Liberty Trust Company… a nationally chartered trust bank tied to the Trump family's crypto venture.

Most investors still haven't processed what that means.

This bank exists to do one thing. Issue, redeem, custody and back USD1… the stablecoin that has now crossed $4 billion in circulation.

And here's the detail almost everyone skipped.

The bank isn't operating yet. There are conditions to satisfy first… capital minimums, an audit manager, a sign-off on the business plan.

Which means the money hasn't moved yet.

That gap—between an approval on paper and a bank actually running—is the entire opportunity.

Because when a federally supervised entity starts converting institutional dollars into a Trump-backed stablecoin, that liquidity has to land somewhere…

History is clear about where. Bitcoin runs. And altcoins detonate.

There's one coin sitting at the center of this ecosystem. It plays the same infrastructure role Uniswap and PancakeSwap played in their earliest days… except this one is wired into a system being accelerated by administration policy.

Smart money is already accumulating. Volume is hitting record highs. And the market cap is still under $2 billion.

My team wrote the full breakdown. Get it here:

Get my #1 coin for the Trump bull run — before the bank opens its doors.

To your massive success,

Bryce Paul
Crypto 101

Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?

Author: Sam Quirke. Article Published: 9/16/2026.

After one of its worst days in recent memory following July’s earnings report, Apple Inc. (NASDAQ: AAPL) has given shareholders little to smile about. However, the past week has been a welcome exception.

Since the company unveiled its latest products last Wednesday, AAPL has jumped around 7% to trade near $330, putting it back within striking distance of its all-time high. For a stock weighed down by concerns about slowing growth and a lagging AI strategy, that’s a notable burst of enthusiasm. The long-awaited launch appears to have struck the right chord.

Jon Najarian's #1 Energy Trade for 2026 (Ad)

Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2 trillion, with Anthropic and OpenAI preparing IPOs of their own.

But Najarian's top pick isn't an IPO. It's a small American company with a $6 billion market cap powering Elon Musk's newest venture, dubbed the Infinite Power Grid.

The full story is laid out in his newly released presentation.

Watch Jon Najarian's full breakdown of this energy trade now.

The question now is whether this marks the start of a more durable uptrend or simply a short-lived sugar rush before recent doubts return. The answer hinges on what actually changed last week and whether it is enough to shift Apple’s trajectory.

Why the Market Warmed to the Launch

The clearest reason for the renewed optimism is that this was a more substantial event than Apple has delivered in a while. The headline act was the Duo, the company’s first-ever folding iPhone. It opens into a tablet-sized screen and, at a starting price near $2,000, establishes an entirely new ultra-premium tier above the existing Pro models.

That plays directly into a strategy investors have come to appreciate. By adding a pricier tier at the top and raising the cost of its Pro phones, which now start at around $1,200, Apple can increase the average price of every iPhone it sells. In a mature market where selling significantly more handsets is difficult, generating more revenue from each sale is the next best thing.

Unsurprisingly, Wall Street analysts are embracing this strategy. TD Cowen, one of the more bullish voices, reiterated its Buy rating and set a fresh $400 price target after last week’s event. From current levels, that represents roughly 20% upside. If shares reach that target in the coming weeks, they would move above July’s all-time high.

The AI Upgrade Angle

Beneath the shiny new hardware lies a subtler reason for optimism: artificial intelligence could give Apple’s enormous customer base a compelling reason to upgrade to higher-priced models. The latest phones rely heavily on new chips and AI features, many of which will not run on older devices.

That matters more than it might seem. By some estimates, well over 800 million iPhones in use cannot support Apple’s newest AI tools at all. That represents a vast pool of potential upgraders, and if AI becomes something customers feel they need, Apple will have a powerful, built-in engine for future sales.

Better still, Apple is pursuing this opportunity without the eye-watering spending some rivals are lavishing on AI. By focusing on on-device processing and its own custom chips instead of building vast data centers, the company can integrate AI into its products while preserving its formidable profitability.

Why the Doubters Still Aren't Convinced

For all that, however, the bears have not gone away. Their central worry is simple: Will any of this actually move the needle in a meaningful way? Foldable phones have been available for years and still account for only about 2% of the market. A folding iPhone may attract attention, but skeptics question whether it can ever become more than a niche product.

There’s also a risk that the Duo shifts demand rather than creating it. If buyers who would have purchased a Pro Max opt for the Duo instead, Apple sells a pricier phone but not necessarily more phones. That would raise its average selling price without increasing the number of devices in use.

Then there is the ever-present tension over pricing. Rising memory costs are squeezing margins across the industry, and while higher prices help Apple absorb those costs, pushing prices too high could prompt customers to hold onto their phones longer. The AI features, meanwhile, remain promising but unproven, with the revamped Siri arriving later than planned.

So, Is the Pop Built to Last?

Taking everything into account, Apple’s rally over the past week appears to be built on something real. The business has a new premium tier, is developing a more visible AI story and has a plausible path to a broader upgrade cycle. This enthusiasm was not pulled from thin air.

The catch is that almost all of it still hinges on one word: scale. The Duo can improve Apple’s product mix even as a niche item, but a true, growth-reviving upgrade wave requires customers to decide that the new phones—and the AI inside them—are things they cannot do without. That has yet to be proven.

For now, the pop looks well-earned rather than fanciful. Whether it hardens into a lasting recovery or fades will depend on how many of those upgrades actually materialize. The coming months—and Apple’s sales—will tell.

3 Healthcare Stocks for 3 Stages of Life

Author: Jessica Mitacek. Article Published: 9/15/2026.

When it comes to investing, there is no one-size-fits-all approach. Strategies vary based on numerous factors, including investors’ risk tolerance, net worth and age. When it comes to stock-picking, that last factor is important.

Conventional wisdom says that younger investors with longer time horizons should focus on decades of exposure to growth stocks. Middle-aged investors may want to reduce their risk profile while seeking out a combination of growth and yield. Older investors tend to focus on income generation.

Jon Najarian's #1 Energy Trade for 2026 (Ad)

Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2 trillion, with Anthropic and OpenAI preparing IPOs of their own.

But Najarian's top pick isn't an IPO. It's a small American company with a $6 billion market cap powering Elon Musk's newest venture, dubbed the Infinite Power Grid.

The full story is laid out in his newly released presentation.

Watch Jon Najarian's full breakdown of this energy trade now.

While higher-volatility growth sectors like tech and communication services don’t necessarily fit the bill, some sectors offer something for every investor, regardless of age. The healthcare sector is one of them. After an unremarkable start to the year, that corner of the market has been on a tear in the second half.

Healthcare’s mix of high-growth drugmakers, defensive operators and reliable dividend payers gives investors several ways to participate in the sector’s recent strength.

For Young Investors: Eli Lilly

Eli Lilly (NYSE: LLY), which was founded in 1876, may not be the first company that comes to mind when younger investors think of growth stocks.

Eli Lilly is the largest member of Big Pharma and the only one with a valuation north of $1 trillion.

However, because of its dynamic portfolio of diabetes, cancer, Alzheimer’s and obesity drugs, it acts like a growth stock.

Its lineup of obesity treatments is a particular driver of that growth. The company makes injectable Zepbound and Foundayo, a daily oral tablet for chronic weight management.

So far this year, LLY has underperformed the market. However, since reaching its year-to-date (YTD) low on April 29, shares have rallied nearly 34%. Over the past five years, the stock has gained around 390%.

Eli Lilly provides a modest dividend that yields 0.61%, or $6.92 per share annually. The company has increased that payout for 11 consecutive years, with a five-year annualized growth rate of 15.18% and a healthy, sustainable payout ratio of 23.22%.

While some of the GLP-1 growth is likely priced into the stocks of companies providing those drugs, the industry has years of increasing demand ahead. Grand View Research forecasts that the global obesity treatment market will undergo a compound annual growth rate (CAGR) of 22.3% from 2025 to 2030, while the global GLP-1 weight loss drug market will see an 18.5% CAGR during the same period.

Of the 30 analysts currently covering LLY, 25 assign it a Buy rating. Overall, the stock receives a consensus Moderate Buy rating and an average 12-month price target that suggests as much as 14% potential upside.

For Middle-Aged Investors: UnitedHealth Group

UnitedHealth Group (NYSE: UNH) has had a well-documented turnaround.

After shedding more than 60% from April 11, 2025, to its five-year low on Aug. 1, 2025, the stock has regained more than 60%, including a market-beating 14% YTD performance so far in 2026.

The company’s Medicaid performance is improving. UnitedHealth expects a margin closer to a 1.1% loss rather than the previously projected 1.7% loss, while management still expects 2026 to be the trough before moving toward breakeven or profitability in 2027.

Regarding Medicare Advantage, CFO Wayne DeVeydt said UnitedHealth’s first-half performance supported its expectation of landing in the upper half of its previously stated 2% to 4% margin range for the year.

Importantly, after a difficult 2025, the company has posted four consecutive earnings beats. After reporting its second-quarter results on July 16, management raised its full-year 2026 outlook to adjusted earnings per share (EPS) of $19.50 to $20. It also raised its outlook for operating earnings at both UnitedHealthcare and Optum Health following a stronger-than-expected quarter.

Of the 27 analysts covering UNH, 21 assign it a Buy rating. Overall, the stock receives a consensus Moderate Buy rating and an average 12-month price target that suggests more than 19% potential upside.

For middle-aged investors, it’s worth noting that this growth is combined with a steady dividend, which UnitedHealth has increased for 15 consecutive years. It yields 2.42%, or $9.28 per share annually. While the payout ratio of nearly 60% could be a concern, UNH’s annualized five-year dividend growth rate is 12.57%.

For Older Investors: Johnson & Johnson

As far as healthcare stocks go, Johnson & Johnson (NYSE: JNJ) is often considered an ideal fit for an income investor’s portfolio.

Having achieved Dividend King status 14 years ago, JNJ yields 2.03%, or $5.36 per share annually.

Its payout ratio of 62.11% is somewhat elevated, and its five-year annualized dividend growth rate of 5.25% isn’t as impressive as those of the other two stocks on this list.

However, JNJ is the quintessential steady portfolio compounder. In addition to its dividend, the stock has posted a 28% YTD gain, and over the past five years, shares are up nearly 60%.

That combination of growth and reliable yield makes it a rarity in a defensive sector like healthcare, offering older investors the best of both worlds.

Of the 25 analysts currently covering JNJ, 19 assign it a Buy rating. Overall, it receives a consensus Moderate Buy rating alongside an average 12-month price target that suggests around 3.5% potential upside.